SEC Form 25-NSE filed by Zomedica Corp.

3/13/25 12:02:46 PM ET

$ZOM

Pharmaceuticals and Biotechnology

Health Care

Get the next $ZOM alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38298

Issuer:	Zomedica Corp.
Exchange:	NYSE AMERICAN LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	100 Phoenix Drive, Suite 125
	Ann Arbor	MICHIGAN	48108
Telephone number:				(734) 369-2555

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Shares

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, NYSE AMERICAN LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-03-13	By	Emily Fuhrman		Senior Analyst, Regulation
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $ZOM alert in real time by email

Date

Price Target

Rating

Analyst

1/6/2023

$6.00

Buy

Dawson James

SEC Form 25-NSE filed by Zomedica Corp.

Chat with this insight

Recent Analyst Ratings for
$ZOM

$ZOM
Press Releases

Fastest customizable press release news feed in the world

Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market

Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone

Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

$ZOM
SEC Filings

Zomedica Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-K filed by Zomedica Corp.